The University of Southampton
University of Southampton Institutional Repository

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study
We report a phase II study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by 90Y Ibritumomab tiuxetan (90Y‐IT) in patients with recurrent follicular lymphoma. Of the 52 patients enrolled, 50 were treated with three cycles of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisolone), followed by 90Y‐IT regimen (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m2 rituximab. The overall response rate was 98% with complete response (CR) 30% and partial response (PR) 68%. 18 patients with a PR following chemotherapy improved to a CR following 90Y‐IT: a conversion rate of 40%. Seven patients with PR following 90Y‐IT subsequently improved to a CR 12–18 months later, leading to an overall CR rate of 44%. With a median follow‐up of 5 years, median progression‐free survival was 23·1 months and overall survival was 77·5% at 5 years. High trough serum rituximab levels (median 112 μg/ml; range 52–241) were attained after four doses of rituximab, prior to 90Y‐IT; this was not found to influence response rates. The treatment was well tolerated with few (13·5%) grade 3 or 4 infective episodes and manageable haematological toxicity. Abbreviated immunochemotherapy followed by 90Y‐IT is an effective and well‐tolerated treatment in recurrent follicular lymphoma patients previously exposed to rituximab. Trial registration: clinicaltrials.gov identifier: NCT00637832.
0007-1048
274-282
Illidge, Timothy
9abbc831-d66d-4288-8dc4-d2e1ad45d782
McKenzie, Hayley
886898e3-8527-4676-96a2-a6362ed529e3
Mayes, Sam
969c4ddb-94b6-4b67-8caa-3f5943d6650a
Bates, Andrew
9717be99-0b39-45f9-bf72-1e44ba2996ac
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Pettengell, Ruth
0799173b-a42a-48e7-ad3c-e55ebe3aab35
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Cozens, Kelly
ad334c90-643c-4e72-a957-7d3d15a938ce
Hampson, Grace
2851734a-01b5-4ada-8446-e20883d23546
Dive, Caroline
3e8ddf48-b8f6-48fb-b557-01f107310660
Zivanovic, Maureen
73b0aa3d-4d72-428f-87b4-bb4cf81f1416
Tipping, Jill
8147e7ed-08b2-4c31-88dc-2788dd644fbb
Gallop-Evans, Eve
a6303804-e3e9-4bd3-8ef2-58bb9a27d0df
Radford, John A.
a896e6ca-6d79-4a63-aa84-6d01f9172e2c
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Illidge, Timothy
9abbc831-d66d-4288-8dc4-d2e1ad45d782
McKenzie, Hayley
886898e3-8527-4676-96a2-a6362ed529e3
Mayes, Sam
969c4ddb-94b6-4b67-8caa-3f5943d6650a
Bates, Andrew
9717be99-0b39-45f9-bf72-1e44ba2996ac
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Pettengell, Ruth
0799173b-a42a-48e7-ad3c-e55ebe3aab35
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Cozens, Kelly
ad334c90-643c-4e72-a957-7d3d15a938ce
Hampson, Grace
2851734a-01b5-4ada-8446-e20883d23546
Dive, Caroline
3e8ddf48-b8f6-48fb-b557-01f107310660
Zivanovic, Maureen
73b0aa3d-4d72-428f-87b4-bb4cf81f1416
Tipping, Jill
8147e7ed-08b2-4c31-88dc-2788dd644fbb
Gallop-Evans, Eve
a6303804-e3e9-4bd3-8ef2-58bb9a27d0df
Radford, John A.
a896e6ca-6d79-4a63-aa84-6d01f9172e2c
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f

Illidge, Timothy, McKenzie, Hayley, Mayes, Sam, Bates, Andrew, Davies, Andrew, Pettengell, Ruth, Stanton, Louise, Cozens, Kelly, Hampson, Grace, Dive, Caroline, Zivanovic, Maureen, Tipping, Jill, Gallop-Evans, Eve, Radford, John A. and Johnson, Peter (2016) Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. British Journal of Haematology, 173 (2), 274-282. (doi:10.1111/bjh.13954). (PMID:26849853)

Record type: Article

Abstract

We report a phase II study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by 90Y Ibritumomab tiuxetan (90Y‐IT) in patients with recurrent follicular lymphoma. Of the 52 patients enrolled, 50 were treated with three cycles of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R‐CVP (rituximab, cyclophosphamide, vincristine, prednisolone), followed by 90Y‐IT regimen (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m2 rituximab. The overall response rate was 98% with complete response (CR) 30% and partial response (PR) 68%. 18 patients with a PR following chemotherapy improved to a CR following 90Y‐IT: a conversion rate of 40%. Seven patients with PR following 90Y‐IT subsequently improved to a CR 12–18 months later, leading to an overall CR rate of 44%. With a median follow‐up of 5 years, median progression‐free survival was 23·1 months and overall survival was 77·5% at 5 years. High trough serum rituximab levels (median 112 μg/ml; range 52–241) were attained after four doses of rituximab, prior to 90Y‐IT; this was not found to influence response rates. The treatment was well tolerated with few (13·5%) grade 3 or 4 infective episodes and manageable haematological toxicity. Abbreviated immunochemotherapy followed by 90Y‐IT is an effective and well‐tolerated treatment in recurrent follicular lymphoma patients previously exposed to rituximab. Trial registration: clinicaltrials.gov identifier: NCT00637832.

This record has no associated files available for download.

More information

Accepted/In Press date: 30 November 2015
e-pub ahead of print date: 5 February 2016
Published date: April 2016
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 405826
URI: http://eprints.soton.ac.uk/id/eprint/405826
ISSN: 0007-1048
PURE UUID: 98ac5706-b663-49ee-8f22-fea7c71798b2
ORCID for Andrew Davies: ORCID iD orcid.org/0000-0002-7517-6938
ORCID for Louise Stanton: ORCID iD orcid.org/0000-0001-8181-840X
ORCID for Kelly Cozens: ORCID iD orcid.org/0000-0001-9592-9100
ORCID for Peter Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 18 Feb 2017 00:20
Last modified: 16 Mar 2024 03:58

Export record

Altmetrics

Contributors

Author: Timothy Illidge
Author: Hayley McKenzie
Author: Sam Mayes
Author: Andrew Bates
Author: Andrew Davies ORCID iD
Author: Ruth Pettengell
Author: Louise Stanton ORCID iD
Author: Kelly Cozens ORCID iD
Author: Grace Hampson
Author: Caroline Dive
Author: Maureen Zivanovic
Author: Jill Tipping
Author: Eve Gallop-Evans
Author: John A. Radford
Author: Peter Johnson ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×